YU Dechao，Co-founder, CEO and President, Innovent Biologics, Inc.Dr. Yu is the inventor of the world’s first oncolytic virus product, OncorineR (an oncology product) and China’s first novel antibody product, ConberceptR (a drug for ocular diseases and oncology), which has made him the only Chinese scientist who has invented and successfully developed two ‘Class I’ drugs in China.Michael Yu, Ph.D., has been Chairman, President and Chief Executive Officer of Innovent Biologics since its inception in 2011. In the past 6 years, Innovent has become the leading biotech company in China, whose growth story has become a phenomenon not only by the rapid pace of product development (4 products in phase III trials by year 6), but also by the landmark deal Innovent has entered collaboration with Eli Lilly & Company in March 2015, in which Innovent out-licensed China’s very first innovative biologics to a MNC with a historic deal size (>$1 billion). Prior to the position, Dr. Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech since its inception in 2006 until 2011. Prior to his return to China, Dr. Yu was Vice President of Research and Development at Applied Genetics (Nasdaq: AGTC) and Calyon, the latter was acquired by Cell Genesys (Nasdaq: CEGE) in 2001 where he worked for three years following the acquisition.